How Engineered Antibodies and Next Generation Imaging Tools are Reshaping Cancer Care with Anna Wu, Ph.D.
Clips
In this episode of On the Edge of Breakthrough: Voices of Cancer Research, Anna Wu, Ph.D., Chair of the Department of Immunology and Theranostics at City of Hope, joins host Monty Pal, M.D., for an engaging discussion on how innovations in antibody engineering and imaging are improving clinicians’ ability to visualize tumors and guide more effective treatment strategies.
Dr. Wu shares insights on her team’s development of engineered antibodies and fast‑clearing mini‑body fragments. These fragments can initially be used for PET imaging and then later paired with therapeutic radioisotopes to precisely target tumors, which help clinicians see where the treatment is going and how well it may work.
She also talks about two exciting initiatives at City of Hope: CEA‑directed agents (targeted cancer therapies) that are being used in clinical imaging and therapy; and PSCA‑targeted radiopharmaceuticals, which are entering first‑in‑human studies for pancreatic and prostate cancers. These new approaches use imaging to zero in on the tumor target, confirm safety, then deliver the radiation therapy directly to cancer cells.